Purpose

Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause pain and discomfort, can block blood flow, may interfere with cancer therapy, and can occasionally be life-threatening.

The purpose of this study is to determine if a daily injection of a blood-thinner, dalteparin, for three months can safely and effectively reduce the frequency of blood clots in patients at increased risk.

Intervention

Dalteparin sodium (Fragmin) 5000IU sq (injections just below the skin) once daily vs. no study drug

Treatment Duration

12 weeks

Number of Visits

Four (Staff will try to schedule visits to coincide with regular oncology clinic visits)

Study Procedures

• Ultrasound of legs (four total)
• Computed tomography (CT) scans of chest (two total)
• Blood draw (four total)

Enrollment Goal

200 Duke patients

Eligibility Requirements

• 18 years or older
• Patients diagnosed with cancer (solid tumor or lymphoma) of all stages
• Patients changing or starting a new chemotherapy regimen

Study Investigators

Nicole M. Kuderer, MD, and Gary H. Lyman, MD

For more information, contact Phillis Scott at 919-668-1094.